ResearcherDalian Medical UniversityActive in the last 2 years
Jinyong Peng
Matched on ORCID iD 0000-0002-6265-2667; OpenAlex author ID A5076653718. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper
Papers 5
- Corrigendum "Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabine resistant pancreatic cancer cells" [P… Co-author DOI 10.1016/j.phymed.2024.156301↗
- Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabine resistant pancreatic cancer cells. Co-author DOI 10.1016/j.phymed.2021.153711↗
- Selaginellin B induces apoptosis and autophagy in pancreatic cancer cells via the JAK2/STAT3 signaling pathway. Co-author PMID 33312355↗
- Anticancer effect of SZC015 on pancreatic cancer via mitochondria-dependent apoptosis and the constitutive suppression of activated nuclear factor κB and STAT3… Co-author DOI 10.1002/jcp.26892↗
- Potent effects of dioscin against pancreatic cancer via miR-149-3P-mediated inhibition of the Akt1 signalling pathway. Last author DOI 10.1111/bph.13718↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Peng Chu · 4 shared papers, 2018–2025 · strength 0.50
- Paper Corrigendum "Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabi… DOI 10.1016/j.phymed.2024.156301↗
- Paper Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabine resistant … DOI 10.1016/j.phymed.2021.153711↗
- Paper Selaginellin B induces apoptosis and autophagy in pancreatic cancer cells via the JAK2/STAT3 signaling pathway. PMID 33312355↗
- Zeyao Tang · 4 shared papers, 2018–2025 · strength 0.50
- Paper Corrigendum "Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabi… DOI 10.1016/j.phymed.2024.156301↗
- Paper Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabine resistant … DOI 10.1016/j.phymed.2021.153711↗
- Paper Selaginellin B induces apoptosis and autophagy in pancreatic cancer cells via the JAK2/STAT3 signaling pathway. PMID 33312355↗
- Xiaodong Ma · 3 shared papers, 2020–2025 · strength 0.43
- Paper Corrigendum "Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabi… DOI 10.1016/j.phymed.2024.156301↗
- Paper Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabine resistant … DOI 10.1016/j.phymed.2021.153711↗
- Paper Selaginellin B induces apoptosis and autophagy in pancreatic cancer cells via the JAK2/STAT3 signaling pathway. PMID 33312355↗
- Abdullah Shopit · 3 shared papers, 2020–2025 · strength 0.43
- Paper Corrigendum "Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabi… DOI 10.1016/j.phymed.2024.156301↗
- Paper Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabine resistant … DOI 10.1016/j.phymed.2021.153711↗
- Paper Selaginellin B induces apoptosis and autophagy in pancreatic cancer cells via the JAK2/STAT3 signaling pathway. PMID 33312355↗
- Xiaohong H. Shu · 2 shared papers, 2021–2025 · strength 0.32
- Paper Corrigendum "Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabi… DOI 10.1016/j.phymed.2024.156301↗
- Paper Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabine resistant … DOI 10.1016/j.phymed.2021.153711↗
- Zhaolin Sun · 1 shared paper, 2020 · strength 0.10
- Yanlin Song · 1 shared paper, 2018 · strength 0.07
- Bin Sun · 1 shared paper, 2018 · strength 0.07
- Xu Han · 1 shared paper, 2017 · strength 0.07
- Lingling Si · 1 shared paper, 2017 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.